Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study)

Next Previous
Trial Profile

A Two-year, Randomized, Controlled, Open-label, Virologic Response Adaptive Design, Multicenter Study to Optimize Antiviral Efficacy of Telbivudine in Adult Patients With HBeAg Positive Chronic Hepatitis B (EFFORT Study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telbivudine (Primary) ; Adefovir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms EFFORT

    • Most Recent Events

    • 06 Apr 2020 According to an Assembly Biosciences media release, results of a retrospective analysis of patients from two Phase IV clinical trials (NCT00962533 and ISRCTN79659320) has been published in Hepatology, the journal of the American Association for the Study of Liver Diseases (AASLD).
    • 06 Apr 2020 Results of a retrospective analysis of patients from two Phase IV clinical trials (NCT00962533 and ISRCTN79659320), presented in an Assembly Biosciences media release.
    • 25 Mar 2020 Results published in the Journal of Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top